These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 35123901)
1. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Martin C; Reynaud-Gaubert M; Hamidfar R; Durieu I; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Lemonnier L; Burnet E; Paillasseur JL; Da Silva J; Burgel PR J Cyst Fibros; 2022 May; 21(3):489-496. PubMed ID: 35123901 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS; Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946 [TBL] [Abstract][Full Text] [Related]
3. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202 [TBL] [Abstract][Full Text] [Related]
4. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C; Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]
6. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R; N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873 [TBL] [Abstract][Full Text] [Related]
7. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population. Smith S; Borchardt M J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861 [No Abstract] [Full Text] [Related]
8. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis. FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329 [TBL] [Abstract][Full Text] [Related]
9. Triple Therapy for Cystic Fibrosis Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D; N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784 [TBL] [Abstract][Full Text] [Related]
10. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610 [TBL] [Abstract][Full Text] [Related]
11. Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Hoy SM Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874 [TBL] [Abstract][Full Text] [Related]
12. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis. McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711 [No Abstract] [Full Text] [Related]
13. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351 [TBL] [Abstract][Full Text] [Related]
14. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM; Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492 [No Abstract] [Full Text] [Related]
16. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey. Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D Respir Med; 2021; 189():106646. PubMed ID: 34673344 [TBL] [Abstract][Full Text] [Related]